THE DUBERSTEIN GROUP INC. for PFIZER INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
TransPacific Partnership negotiations - Executive Branch action re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Medicare/Medicaid MMM
Medicare Part D rebates - Proposed legislation re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Defense DEF
Homeland Security and Defense issues surrounding readiness for a chemical nerve agent attack or industrial accident - Proposed legislation re this issue; Executive Branch actions re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Taxation/Internal Revenue Code TAX
Corporate tax reform, including international taxes, tax extenders, repatriation, and patent box - Proposed legislation re these issues. *Foreign-controlled corporations look-through permanency - HR 2735, To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations. *Excess returns - HR 2495, Tax Equity and Middle Class Fairness Act of 2011. *Offshoring - HR 2280, Offshoring Prevention Act; S 45, Offshoring Prevention Act. *Reinvestment of foreign earnings - S 1671, Foreign Earnings Reinvestment Act. *Tax havens - S 1346, Stop Tax Haven Abuse Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| ERIC UELAND | — |
Health Issues HCR
Implementation of the Patient Protection and Affordable Care Act, including Supreme Court case and coverage issues - Proposed legislation re these issues; Executive Branch actions re these issues. Congressional investigation regarding the Patient Protection and Affordable Care Act. *FDA funding - HR 5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013; S 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. *Antimicrobial resistence. *Repeal Independent Payment Advisory Board provision of PL 111-148, PL 111-152 - HR 452, Medicare Decisions Accountability Act of 2011; S 668, Health Care Bureaucrats Elimination Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Pharmacy PHA
Drug shortages - Proposed legislation re these issues. Opiate abuse - HR 1316, Stop Oxy Abuse Act of 2011; HR 2119, Ryan Creedon Act of 2011; HR 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011; HR 1065, Pill Mill Crackdown Act of 2011; S 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; Executive Branch action re this issue. Pharmaceutical issues, including tracking and tracing medicines, fostering competition between generic and brand-name pharmaceutical manufacturers - HR 5651, Food and Drug Administration Reform Act of 2012; S 3187, Food and Drug Administration Safety and Innovation Act. Incentives to develop antibiotics - HR 2182, Generating Antibiotic Incentives Now Act of 2011; S 1734, Generating Antibiotic Incentives Now Act of 2011. Establish criminal penalties for trafficking in counterfeit drugs - HR 3468, Counterfeit Drug Penalty Enhancement Act of 2011; S 1886, Counterfeit Drug Penalty Enhancement Act of 2011. National Center for Advancing Transformational Sciences at FDA; agreement to review compounds for potential new uses - Executive Branch actions re these issues. *Follow-on biologics generally. *Certified Importer Program. *Drug safety - HR 1483, Drug Safety Enhancement Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL BERMAN | — |
| STEVEN CHAMPLIN | — |
| KENNETH DUBERSTEIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
| MARTI THOMAS | — |
| ERIC UELAND | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.